What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock is trading lower on Thursday; however, there is no news to justify the movement. The stock could possibly be down on profit-taking after the stock closed nearly 15% higher on Wednesday.
On Tuesday, the company shared positive results from its Phase 1b clinical trial for its lead candidate, PH-762.
PH-762 Shows 85% Pathological Response Rate
Phio Pharmaceuticals’ lead clinical program is PH-762 (often referred to in the context of their INTASYL platform), which is an investigational, self-delivering RNAi compound designed to treat skin cancers. It works by silencing the PD-1 gene to enhance the immune system’s ability to kill tumor cells.
Phio Pharmaceuticals recently announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762, which showed an 85% pathological response rate at the highest dose concentration.
The trial involved 22 patients with cutaneous carcinomas, and the Safety Monitoring Committee reported no serious adverse events, indicating a promising outlook for the drug.
The company is targeting an FDA submission for guidance on clinical study design for PH-762 in the second quarter of 2026, with plans to commence manufacturing of cGMP material by the second half of 2026. These developments highlight the potential of PH-762 as a non-surgical treatment for skin cancers.
PHIO Mixed Technical Indicators
The stock is currently trading 18.4% above its 20-day simple moving average (SMA) but is 18.3% below its 100-day SMA, indicating mixed signals in the short to medium term. Over the past 12 months, shares have decreased by approximately 29.51% and are currently positioned closer to their 52-week lows than highs.
The RSI is at 66.61, which is considered neutral territory, while the MACD is above its signal line, indicating bullish momentum. The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock.
- Key Resistance: $1.50
- Key Support: N/A
Analyst Consensus & Recent Actions:
The stock carries a Buy Rating with an average price target of $10.67. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Maintains Target to $14.00) (Feb. 10)
PHIO Price Action: Phio Pharma shares were down 4.65% at $1.23 during premarket trading on Thursday.
Photo by Aunt Spray via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Reportedly, the US urges Japan to "increase" defense spending; Tokyo considers a 3.5% GDP target, bond market and yen come under pressure first
Under pressure from the United States, Japan is considering setting a new medium-term defense spending target, planning to increase its defense expenditure to 3.5% of GDP to align with NATO and other U.S. allies.
The logic of "cheap yen financing" is changing! Funds are reallocating "carry trades" as Swiss franc and Swedish krona compete for the funding currency position
The appeal of yen financing has diminished, and carry traders have recently turned their attention to the franc and the krona. With the yen’s recent surge making it a less reliable investment option, currencies such as the Swedish krona and Swiss franc are becoming primary funding choices for carry trades.
Crypto Regulation Deal Collapses: 5 Altcoins to Watch Before Volatility Turns Into the Next Buying Opportunity
Crypto prices
More
